Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy

Drug-drug interactions among Thai HIV-positive transgender women undergoing feminizing hormone therapy and antiretroviral therapy: the iFACT study

(2020) Akarin Hiransuthikul et al.   CLINICAL INFECTIOUS DISEASES

Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy

(2020) Lauren R Cirrincione et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Tenofovir Alafenamide

(2020) Jenna Yager et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Decreased tenofovir diphosphate concentrations in a transgender female cohort: Implications for HIV pre-exposure prophylaxis (PrEP)

(2019) Mackenzie L Cottrell et al.   CLINICAL INFECTIOUS DISEASES

Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir

(2019) Kristina M Brooks et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

High Rates of PrEP Eligibility but Low Rates of PrEP Access Among a National Sample of Transmasculine Individuals

(2019) Sarit A. Golub et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Gap Between Willingness and Uptake

(2019) Tonia Poteat et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Drug‐drug interactions between feminizing hormone therapy and pre‐exposure prophylaxis among transgender women: the iFACT study

(2019) Akarin Hiransuthikul et al.   Journal of the International AIDS Society

High risk and low uptake of pre‐exposure prophylaxis to prevent HIV acquisition in a national online sample of transgender men who have sex with men in the United States

(2019) Sari L Reisner et al.   Journal of the International AIDS Society

Are Standard Doses of Renally-Excreted Antiretrovirals in Older Patients Appropriate: A PBPK Study Comparing Exposures in the Elderly Population With Those in Renal Impairment

(2019) M. De Sousa Mendes et al.   Drugs in research & development

Transgender women on oral HIV pre‐exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men

(2019) Eugenie Shieh et al.   Journal of the International AIDS Society

Long-acting injectable cabotegravir for the prevention of HIV infection

(2019) Meredith E. Clement et al.   Current Opinion in HIV and AIDS

Effect of Dose and 5α-Reductase Inhibition on the Circulating Testosterone Metabolite Profile of Men Administered Oral Testosterone

(2018) Abdul Basit et al.   CTS-Clinical and Translational Science

Inhibition of carboxylesterase 2 (CES2) by sofosbuvir: Metabolism-reduced potency, in vivo inhibition and reduced activation of the anti-HIV drug tenofovir disoproxil

(2018) Yuanjun Shen et al.   Drug Metabolism and Pharmacokinetics

17β-estradiol suppresses carboxylesterases by activating c-Jun/AP-1 pathway in primary human and mouse hepatocytes

(2018) Lili Wu et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1

(2018) Tristan D. McPherson et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate

(2018) Christine E MacBrayne et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study

(2018) Roberto Vita et al.   MATURITAS

Tenofovir Diphosphate in Dried Blood Spots is Strongly Associated with Viral Suppression in Individuals with HIV infection

(2018) Jose R Castillo-Mancilla et al.   CLINICAL INFECTIOUS DISEASES

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

(2018) Raphael J. Landovitz et al.   PLOS MEDICINE

Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline

(2017) Wylie C Hembree et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Covalent inhibition of carboxylesterase-2 by sofosbuvir and its effect on the hydrolytic activation of tenofovir disoproxil

(2017) Yuanjun Shen et al.   JOURNAL OF HEPATOLOGY

Spironolactone

(2017) Laura Carone et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Development of a Novel Formulation That Improves Preclinical Bioavailability of Tenofovir Disoproxil Fumarate

(2017) Melynda E. Watkins et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State

(2016) Sharon M. Seifert et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)

(2016) Craig W. Hendrix et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

(2016) Adrian S. Ray et al.   ANTIVIRAL RESEARCH

Drug–Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV

(2016) Kimberly K. Scarsi et al.   DRUG SAFETY

METABOLIC EFFECTS OF HORMONE THERAPY IN TRANSGENDER PATIENTS

(2016) John David Fernandez et al.   Endocrine Practice

Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial

(2016) Julien Fonsart et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Different effect of testosterone and oestrogen on urinary excretion of metforminviaregulating OCTs and MATEs expression in the kidney of mice

(2016) Rui He et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters

(2016) Josef Reznicek et al.   XENOBIOTICA

Exposure of LS-180 Cells to Drugs of Diverse Physicochemical and Therapeutic Properties Up-regulates P-glycoprotein Expression and Activity

(2016) Alaa H Abuznait et al.   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

Transdermal delivery of testosterone

(2015) Jonathan Hadgraft et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Effects of Cross-Sex Hormone Treatment on Transgender Women and Men

(2015) Madeline B. Deutsch et al.   OBSTETRICS AND GYNECOLOGY

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam

(2015) Melinda J. Reese et al.   XENOBIOTICA

Formulation and pharmacology of long-acting cabotegravir

(2015) Christine Trezza et al.   Current Opinion in HIV and AIDS

HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial

(2015) Madeline B Deutsch et al.   Lancet HIV

Population Pharmacokinetics of Emtricitabine in HIV-1-Infected Adult Patients

(2014) Elodie Valade et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Sex Hormones Regulate Tenofovir-Diphosphate in Female Reproductive Tract Cells in Culture

(2014) Zheng Shen et al.   PLoS One

Sex hormones in the modulation of irritable bowel syndrome

(2014) Agata Mulak   WORLD JOURNAL OF GASTROENTEROLOGY

Common clinical conditions – age, low BMI, ritonavir use, mild renal impairment – affect tenofovir pharmacokinetics in a large cohort of HIV-infected women

(2013) Sanjiv M. Baxi et al.   AIDS

Men and women, so different, so similar: observations from cross-sex hormone treatment of transsexual subjects

(2013) L. J. Gooren et al.   ANDROLOGIA

Estradiol Regulation of Nucleotidases in Female Reproductive Tract Epithelial Cells and Fibroblasts

(2013) Zheng Shen et al.   PLoS One

Low Body Weight in Females Is a Risk Factor for Increased Tenofovir Exposure and Drug-Related Adverse Events

(2013) Cristina Gervasoni et al.   PLoS One

Worldwide burden of HIV in transgender women: a systematic review and meta-analysis

(2012) Stefan D Baral et al.   LANCET INFECTIOUS DISEASES

Emtricitabine-Tenofovir Concentrations and Pre-Exposure Prophylaxis Efficacy in Men Who Have Sex with Men

(2012) P. L. Anderson et al.   Science Translational Medicine

Molecular Mechanism of Renal Tubular Secretion of the Antimalarial Drug Chloroquine

(2011) Fabian Müller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Does sex matter? The influence of gender on gastrointestinal physiology and drug delivery

(2011) Ana C. Freire et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection

(2010) P. L. Anderson et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Estradiol and Progesterone-Mediated Regulation of P-gp in P-gp Overexpressing Cells (NCI-ADR-RES) and Placental Cells (JAR)

(2009) Lisa D. Coles et al.   MOLECULAR PHARMACEUTICS

Lack of Effect of Tenofovir Disoproxil Fumarate on Pharmacokinetics of Hormonal Contraceptives

(2009) Brian P Kearney et al.   PHARMACOTHERAPY

Relevance of the Organic Cation Transporters 1 and 2 for Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection

(2008) N. Jung et al.   DRUG METABOLISM AND DISPOSITION

Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein

(2008) Laurence Bousquet et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Renal excretion of emtricitabine II. Effect of trimethoprim on emtricitabine excretion: In vitro and in vivo studies

(2008) Tomoko Nakatani‐Freshwater et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Renal excretion of emtricitabine I: Effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion

(2008) Tomoko Nakatani‐Freshwater et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Oral estrogen therapy in postmenopausal women is associated with loss of kidney function

(2008) Sofia B. Ahmed et al.   KIDNEY INTERNATIONAL